3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Mucositis
4
Hematologic Neoplasms
3
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Thrombocytopenia
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neutropenia
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphopenia
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Graft vs Host Disease
1
Cytopenia
1
Anemia
1
Interventions
Cyclophosphamide
17
blinatumomab
16
fludarabine
13
Vincristine
11
Cytarabine
10
tisagenlecleucel
8
pegaspargase
8
nilotinib
8
Methotrexate
8
Inotuzumab Ozogamicin
8
Clofarabine
8
venetoclax
7
Dexamethasone
7
asparaginase erwinia chrysanthemi recombinant
6
Dasatinib
6
Azacitidine
5
AP 1903 reagent
5
aflibercept
4
Mercaptopurine
4
Imatinib Mesylate
4
Filgrastim
4
Etoposide
4
Drug Therapy
4
Daunorubicin
4
ponatinib
3
Sensitivity and Specificity
3
Mitoxantrone
3
Immunotherapy, Adoptive
3
Granulocyte Colony-Stimulating Factor
3
CPX-351
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
angiotensin I (1-7)
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled